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ORIGINAL ARTICLE
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ABSTRACT
Background: Upon FDA/EMEA registration for hepatocellular carcinoma (HCC), sorafenib received a
broader therapeutic indication than the eligibility criteria of the landmark SHARP trial. This allowed
treatment of SHARP non-eligible patients in daily clinical practice.
Aim: To assess sorafenib efficacy and safety in SHARP eligible and non-eligible patients, and determine
the validity of the current therapeutic indication as described by the FDA/EMEA.
Patients and methods: Consecutive patients treated with sorafenib for advanced HCC at two Dutch ter-
tiary referral centers between 2007 and 2016 were analyzed retrospectively. Primary outcome was overall
survival (OS). Secondary outcomes were time to progression (TTP), response rate, adverse events and rea-
sons for discontinuation. Outcomes were compared between SHARP eligible and non-eligible patients.
Results: One hundred and ninety-three of 257 (75%) patients were SHARP eligible. SHARP eligible
patients (9.5 months, 95% CI 7.7–11.3) had a longer median OS than non-eligible patients (5.4 months,
95% CI 3.6–7.1) (log-rank p< .001). SHARP non-eligible patients were more often Child–Pugh B, had
higher AST and ALT levels and developed more grade 3–4 liver dysfunction (44 versus 23%, p< .001)
during treatment. SHARP ineligibility remained the strongest predictor of OS (HR 1.78, 95% CI
1.32–2.41) and an independent predictor of TTP (HR 1.45, 95% CI 1.05–2.00) in multivariable analysis.
Conclusions: Landmark trial outcomes of sorafenib for HCC are reproducible in daily practice, pro-
vided that the SHARP eligibility criteria are respected. Based on the findings of this and previous stud-
ies, sorafenib usage should be restricted to Child–Pugh A patients.
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Introduction
For almost a decade, the multikinase inhibitor sorafenib has
been the only registered treatment for advanced hepatocel-
lular carcinoma (HCC). Implementation of sorafenib as stand-
ard treatment for advanced HCC is based on the results of
two randomized phase III trials: the Sorafenib Hepatocellular
Carcinoma Assessment Randomized Protocol (SHARP) trial
and the parallel Sorafenib Asian-Pacific (AP) trial [1,2]. Both
studies demonstrated a sorafenib survival benefit of 3 months
compared with placebo in strictly selected patients. HCC
develops mostly in patients with liver cirrhosis, thus only
patients with well-preserved liver function (Child–Pugh A)
were eligible for study participation. Presence or absence of
underlying cirrhosis was not specified. Accordingly, the cur-
rent guidelines recommend sorafenib treatment for
advanced HCC in patients with Child–Pugh A liver function
only, without specifying the presence or absence of
underlying cirrhosis [3,4]. Nonetheless, the Food and Drug
Administration (FDA) and the European Medicines Evaluation
Agency (EMEA) gave sorafenib a broader therapeutic indica-
tion than the eligibility criteria of the landmark SHARP trial
[5]. The guideline endorsed Barcelona Clinic Liver Cancer
(BCLC) staging system does not exclude Child–Pugh B
patients for sorafenib treatment [6]. Consequently, several
real-life studies showed that sorafenib is currently prescribed
to a broad spectrum of patients, including substantial num-
bers (12.5–34%) of Child–Pugh B patients [7–16]. It is well-
established that patients with Child–Pugh B liver function
have significantly poorer outcomes, although sorafenib tox-
icity seems not related to Child–Pugh status [9,12,15]. Still, in
absence of randomized-controlled trials, the exact benefit in
patients not-meeting the SHARP eligibility criteria, specifically
in Child–Pugh B patients, remains controversial. Real-life
studies in some tumor types (i.e., colorectal and prostate
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cancer) have shown decreased outcomes when systemic
therapies are given outside the landmark trial eligibility crite-
ria [17,18], whereas outcomes were comparable in patients
with bile tract cancer [19]. A direct comparison between
SHARP eligible and non-eligible subgroups in advanced HCC
has not been conducted. Hence, it remains unknown
whether sorafenib treatment of a substantial numbers of
SHARP ineligible patients, which are exposed to sorafenib
toxicity and results in significant healthcare costs, is benefi-
cial. Hence, this retrospective multicenter study aims to
assess the real-life efficacy and safety of sorafenib in
advanced HCC, comparing SHARP eligible and non-eligible
subgroups; and to determine whether the current sorafenib
therapeutic indication as described by EMEA/FDA is valid
based on the current evidence.
Patients and methods
Study population
All consecutive patients, 18 years old, evaluated at two ter-
tiary HCC referral centers in the Netherlands [Academic
Medical Center (AMC), Amsterdam, and Erasmus University
Medical Center (EMC), Rotterdam] who received at least one
dose of sorafenib for advanced HCC between May 2007 and
December 2016 were included in this retrospective study.
Study-based sorafenib was allowed, but patients who
received study-based selective internal radio-embolization
therapy (SIRT) combined with sorafenib were excluded from
this analysis [20].
HCC diagnosis was established histologically or by the
American Association for the Study of Liver Diseases (AASLD)
imaging criteria [21]. Absence or presence of underlying cir-
rhosis was established on criteria proposed by Mittal et al.
[22]. Patients were staged by four-phase computed tomog-
raphy (CT) or dynamic contrast-enhanced magnetic reson-
ance imaging (MRI) and discussed at a multidisciplinary
meeting. Patients were considered for treatment with sorafe-
nib according to the BCLC guidelines [3]. HIV infection was
not a contraindication for treatment. Following the indica-
tions provided by the manufacturer, patients received sorafe-
nib 400mg twice daily (BID), but were allowed to receive
lower starting doses (200mg twice daily), toxicity-adjusted
dosing and treatment interruptions at the discretion of the
medical oncologist to cope with drug-related adverse events
[5]. The Institutional Review Board (IRB) of the AMC (refer-
ence number W17_420#17.488) approved the study and a
waiver for informed consent was given.
Data collection
Potential patients were identified using keywords and diag-
nostic codes from the electronic patient record and phar-
macy records. Included keywords were ‘hepatocellular
carcinoma’, ‘HCC’, ‘malignancy liver’, ‘liver neoplasm’ and ‘liver
malignant neoplasm’. Medical records were reviewed and
clinical data was manually extracted. Extracted data included
previous treatments, baseline patient and tumor
characteristics and treatment details including treatment
emergent adverse events (AE), which was prospectively
monitored as part of standard care. Efforts were made to col-
lect missing data, for example by contacting referring hospi-
tals for additional data on referred patients.
SHARP eligibility criteria
Subgroups were made based on meeting or not meeting the
eligibility criteria of the SHARP trial [2]. These criteria are
shown in Figure 1. In summary, patients were required to
have advanced stage HCC or intermediate stage HCC which
was not or no longer eligible for surgical or locoregional
therapies, without previous systemic therapy for HCC. SHARP
eligible patients were required to have an ECOG PS 0-2,
Child–Pugh A liver function and adequate renal and hemato-
logical function. The actual life expectancy was not men-
tioned in the files, but was considered to be within the limits
of the SHARP eligibility criteria (12 weeks) based on
descriptive data. Patients violating one or more SHARP eligi-
bility criteria were assigned to the ‘SHARP non-eligible sub-
group and patients meeting all criteria were assigned to the
‘SHARP eligible’ subgroup. Patients who could not be
assigned to a subgroup due to missing data were excluded
from this study.
Outcome measures
The primary outcome, overall survival (OS), was calculated
from the date of the first dose of sorafenib until death or
censored on the last known date to be alive. Survival status
was checked in the electronic medical record and verified by
using the municipal records database on 17 January 2018.
Time to progression (TTP) was defined as the time from
start of sorafenib treatment until clinical or radiological disease
progression. Radiological response evaluation was performed
every 2–3 months as part of standard of care and assessed by
experienced abdominal radiologists using the Response
Evaluation Criteria in Solid Tumors (RECIST 1.1) [23].
Progression-free patients were censored at the time of last
radiological evaluation. Patients who died or were lost to fol-
low-up before first radiological evaluation, were excluded from
TTP analysis. In response evaluation, all patients who showed
clinically progressive disease in the absence of radiological
evaluation were considered to have progressive disease. All
adverse events were classified according to the National
Cancer Institute’s Common Toxicity Criteria (NCI-CTC v4.03)
[24]. Liver dysfunction was defined as occurrence or deterior-
ation of hyperbilirubinemia, ascites or encephalopathy.
Statistical analysis
Continuous variables were expressed as medians and ranges,
and categorical variables as absolute and relative frequen-
cies. The Pearson’s chi-square or Fisher’s exact test where
appropriate, were used to compare categorical data in the
SHARP eligible and non-eligible subgroups. Continuous data
was compared using the Student’s t-test or Mann–Whitney
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U-test, where appropriate. The Kaplan–Meier method and
log-rank tests were used to estimate and compare OS and
TTP curves. Cox proportional hazard regression analysis was
used to calculate hazard ratios (HRs) and assess the associ-
ation of baseline variables, including literature reported pre-
dictors, with OS and TTP. All predictors with a two-sided
p value <.05 in univariate analysis were included in a subse-
quent multivariable model in which correlated predictors
were adjusted to reduce overlapping variance. In order to
identify the impact of the separate SHARP eligibility criteria,
we performed an exploratory univariate analysis of the indi-
vidual criteria separately. A two-sided p value <.05 was con-
sidered statistically significant. Statistical analyses were
performed using IBM SPSS statistics (version 23.0; IBM Corp.,
Armonk, NY).
Results
Patient characteristics
Between May 2007 and December 2016, a total of 323
patients with advanced HCC were treated with sorafenib. Of
these, 66 patients (20%) were excluded due to incomplete
data (n¼ 47) or because they received combined SIRT and
sorafenib treatment (n¼ 19) (Figure 1). The remaining 257
patients formed the study cohort of whom baseline patient
and tumor characteristics are summarized in Table 1. The
majority of patients had liver cirrhosis (79%), and 218
patients (85%) were in the Child–Pugh A class. The most
common etiological factors were alcohol (34%), followed by
hepatitis B virus infection (HBV; 16%) and hepatitis C virus
infection (HCV; 16%). At the start of sorafenib treatment,
most patients had advanced stage HCC (73%) and 93
patients (36%) received prior treatment for HCC, mainly TACE
(21%). In total, 193 of the 257 (75%) were considered SHARP
eligible. Reasons for non-eligibility of the other 64 patients
are listed in Figure 1. SHARP non-eligible patients had more
often Child–Pugh B liver function with lower albumin and
higher bilirubin, aspartate transaminase (AST) and alanine
transaminase (ALT) levels. Less common reasons for SHARP
ineligibility were prior systemic treatment for HCC (n¼ 4),
low platelet count (n¼ 4) or low hemoglobin (n¼ 3). SHARP
non-eligible patients were younger (63 versus 66 years,
p¼ .040), but other baseline clinical and tumor characteristics
were comparable between subgroups.
Overall survival
After a median follow-up of 45.8 months (range 0.2–63.2),
232 of 257 (90%) patients had died. The median OS for all
patients receiving sorafenib was 8.4 months (95% CI 6.9–9.9).
The median OS in the SHARP eligible subgroup was
Figure 1. Study flowchart.
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9.5 months (95% CI 7.7–11.3) compared with 5.4 months
(95% CI 3.6–7.1) in the SHARP non-eligible subgroup (log-
rank p< .001; Figure 2A).
In univariable Cox regression analysis (Table 3), not meet-
ing the SHARP inclusion criteria was the strongest predictor
of an increased risk of mortality [hazard ratio (HR)¼ 1.81,
95% CI 1.35–2.44]. Other baseline factors that were associ-
ated with an increased risk of mortality were ECOG perform-
ance status 2, tumor size >72mm (above median),
macrovascular invasion (MVI) and a-fetoprotein (AFP)
400 ng/ml, whereas patients that received prior HCC treat-
ment had a better prognosis (HR 0.67, 95% CI 0.51–0.88). In
subsequent multivariable analysis, not meeting the SHARP
inclusion criteria (HR¼ 1.78, 95% CI 1.32–2.41), MVI
(HR¼ 1.34, 95% CI 1.02–1.76) and AFP 400 (HR¼ 1.60, 95%
CI 1.22–2.11) were independently associated with reduced
survival. An additional exploratory analysis aimed at assess-
ing the impact of the individual SHARP eligibility criteria
(Supplementary Table S1), showed that Child–Pugh B (HR 2.
03, 95% CI 1.40–2.95), hemoglobin <5.3mmol/l (HR 13.85,
95% CI 4.16–46.06), bilirubin >51.3 mmol/L (HR 2.46, 95% CI
1.16–5.25), AST >5 ULN (HR 2.66, 95% CI 1.72–4.11), ALT
>5 ULN (HR 1.18, 95% CI 0.52–2.67) and creatinine >1.5
ULN (HR 8.57, 95% CI 2.08–35.39) were associated with
Table 1. Baseline characteristics of all, SHARP eligible and non-eligible patients.
Variable All patients, N¼ 257 Eligible, N¼ 193 Non-eligible, N¼ 64 p valuea
Age, median (range) (years) 65 (26–84) 66 (26–84) 63 (27–79) .040
Male, n (%) 208 (81) 161 (83) 47 (73) .098
Etiology, n (%)
Alcohol 87 (34) 67 (35) 20 (31) .650
HBV 40 (16) 30 (15) 10 (16) .998
HCV 41 (16) 31 (16) 10 (16) .934
NAFLD/NASH 20 (8) 17 (9) 3 (5) .420
Other/unknown 15 (6) 9 (5) 6 (9) .215
Cirrhosis, n (%) 203 (79) 148 (77) 55 (86) .081
Child–Pugh class, n (%)b <.001
A 218 (85) 193 (100) 25 (39)
B 35 (14) NA (0) 35 (55)
ECOG performance status, n (%) .558
0 81 (32) 64 (33) 17 (27)
1 153 (60) 113 (59) 40 (63)
2 23 (9) 16 (8) 7 (11)
BCLC stage prior to start sorafenib, n (%) .300
B (intermediate) 69 (27) 55 (29) 14 (22)
C (advanced) 188 (73) 138 (72) 50 (78)
Number of nodes, n (%) .097
1 node 53 (21) 41 (21) 12 (19)
2–3 nodes 60 (23) 66 (34) 14 (22)
>3 nodes or diffuse infiltrating 20 (8) 86 (45) 38 (59)
Size of largest node, mm (range) 72 (10–230) 70 (12–225) 77 (10–230) .143
Macroscopic vascular invasion, n (%) 107 (42) 79 (41) 28 (44) .692
Extend of disease .085
Confined to liver 108 (42) 87 (45) 21 (33)
Extrahepatic spread 149 (58) 106 (55) 43 (67)
Laboratory analysis
AFP, ng/ml, median (range) 179 (2–1201500) 158 (2–1201500) 244 (3–688200) .137
AFP 400 ng/ml, n (%) 109 (42) 81 (42) 28 (44) .727
Hemoglobin (mmol/L), median (range) 8.2 (4.9–10.8) 8.3 (5.6–10.8) 7.8 (4.9–10.5) .001
Thrombocytes (109), median (range) 187 (52–846) 188 (62–672) 175 (52–846) .761
PT (sec), median (range) 12.5 (9.8–17.5) 12.3 (9.8–16.4) 13.0 (10.7–17.5) <.001
Creatinine (mmol/L), median (range) 72 (41–247) 74 (41–151) 68 (41–247) .227
Albumin (g/dl), median (range) 40 (23–50) 40 (30–50) 35 (23–47) <.001
Bilirubin (mmol/L), median (range) 14 (3–75) 13 (3–40) 22 (3–75) <.001
AST (U/L), median (range) 69 (17–697) 64 (17–198) 126 (29–697) <.001
ALT (U/L), median (range) 47 (9–493) 45 (9–224) 51 (20–493) .012
Received prior treatment, n (%) 93 (36) 75 (39) 18 (28) .121
Liver transplantation 5 (2) 5 (3) 0 (0) .336
Surgical resection 26 (10) 23 (12) 3 (5) .149
RFA 36 (14) 28 (15) 8 (13) .836
TACE 53 (21) 41 (21) 12 (19) .669
SIRT 1 (<1) 1 (<1) 0 (0) 1.00
Systemic therapy 4 (2) NA 4 (6) .004
ap value applies to the ‘meeting’ versus ‘not meeting’ groups. p values <0.05 are highlighted in bold.
bMissing in four patients.
AFP: a-fetoprotein; ALT: alanine transaminase; AST: aspartate transaminase; BCLC: Barcelona Clinic Liver Cancer classification; ECOG: Eastern Cooperative
Oncology Group; HBV: hepatitis virus B; HCV: hepatitis virus C; NA: non-applicable; NAFLD/NASH: non-alcoholic fatty liver disease/non-alcoholic steatohepatitis;
PT: prothrombin time; RFA: radiofrequent ablation; SHARP: Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol; SIRT: selective internal radi-
ation therapy; TACE: transcatheter arterial chemoembolization.
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reduced OS. A multivariable analysis was not conducted due
risk of collinearity of multiple violations, and limited sample
size of subgroups.
TTP and response rate
Data on TTP (Figure 2(b)) was available in 224 patients
(87%); 33 patients (13%) died or were lost to follow-up
before clinical or radiological disease progression. Overall,
the median TTP was 3.8 months (95% CI 2.9–4.6). SHARP eli-
gible patients had a significant longer TTP (4.3 months, 95%
CI 3.1–5.6) than non-eligible patients (3.0 months, 95% CI
1.7–4.4) (log-rank p¼ .019). After correction for other univari-
able predictors (HBV, MVI and AFP 400), not meeting the
SHARP eligibility criteria remained an independent predictor
of poor TTP (HR 1.45, 95% CI 1.05–2.00) (Supplementary
Table S2). The best radiological response according to RECIST
1.1 was not statistically different between eligible and non-
eligible subgroups (Table 2).
Treatment details and adverse events
Treatment details and adverse events are summarized in
Table 2. Median duration of sorafenib treatment was
13 weeks (range 0–225 weeks) with a median maximum-
tolerated dose of 200mg twice daily, reflecting that the
majority of patients (59%) did not reach the maximum dose.
The most common treatment emergent AE’s (all grades)
were gastrointestinal (37%), liver dysfunction (35%), asthenia
(30%) and skin toxicity (34%). The most common grade III/IV
AE’s were liver dysfunction (28%), followed by gastrointes-
tinal (13%) skin toxicity (11%). During sorafenib treatment,
liver dysfunction occurred more frequently in the SHARP
non-eligible patients (56 versus 28%, p< .001) compared
with SHARP eligible patients. Non-eligible patients developed
more often grade 3–4 liver dysfunction (44 versus 23%,
p¼ .001), but maximum-tolerated sorafenib dose and AE’s
were comparable between subgroups. Patients who were
SHARP non-eligible showed a trend towards shorter treat-
ment duration (9 versus 13 weeks, p¼ .052) and terminated
treatment more often due to combined progression and AE’s
(38 versus 22%, p¼ .030). In SHARP eligible patients, the
main reason for permanent discontinuation was disease pro-
gression (54%).
Discussion
We showed that SHARP eligible patients treated in daily clin-
ical practice had an OS similar to those treated in the SHARP
trial (9.5 versus 10.7 months, respectively), whereas SHARP
non-eligible patients had significantly reduced survival
(5.4 months), reduced TTP and more liver dysfunction dur-
ing treatment.
In our cohort, a minority of patients (25%) did not meet
the SHARP eligibility criteria, mainly due to Child–Pugh class
B liver function or serum AST/ALT values exceeding five
times the upper limit of normal. This suggests that the
observed survival difference, between SHARP eligible and
non-eligible patients can be explained by more compro-
mised liver function in the latter subgroup. Likewise, there
was an increased occurrence of (severe) liver dysfunction
whereas maximum-tolerated dose and other toxicity types
were comparable. Hence, this study confirms the remarks
made by the authors of both sorafenib landmark studies,
which stressed that restricting enrollment to Child–Pugh A
patients, could have potentially prevented deaths related to
advanced liver disease masking the effects of sorafenib [1,2].
Despite these remarks and the guidelines advising sorafe-
nib treatment of advanced HCC in Child–Pugh A patients
only [3], multiple cohort studies showed that prescription to
Child–Pugh B patients has not been uncommon (12–44%,
Table 4) in the past decade [9,12,15]. As sorafenib toxicity in
these patients is comparable to Child–Pugh A patients, sora-
fenib seems a safe treatment option; however, safety alone is
not enough to consider sorafenib as standard of care. Our
study validates the findings of a series of previous studies,
both retrospective and prospective (Table 4), showing that
Child–Pugh B patients have a poor outcome on sorafenib
treatment. Interestingly, the outcomes of SHARP non-eligible
patients treated with sorafenib were inferior to historic
cohorts of SHARP eligible patients receiving placebo
(7.9 months) [2] and comparable to patients with Child–Pugh
B receiving best-supportive care (BSC) only (5 months) [3,25].
Figure 2. (a) Overall survival and (b) time to progression in SHARP eligible and
SHARP non-eligible subgroups. Thirty-three patients were not evaluable for
TTP analysis.
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This suggests that sorafenib is non-superior to BSC in
patients with more advanced liver disease. Despite the multi-
tude of studies counting almost 5000 patients treated with
sorafenib, including more than 1100 Child–Pugh B patients,
the conclusions on the usage in these patients remain
conflicting (Table 4). Ideally a randomized placebo-controlled
trial should be conducted to determine the efficacy in
Child–Pugh B patients. Unfortunately, such an initiative
(BOOST trial) had to be terminated prematurely due to slow
enrollment, demonstrating the difficulty in recruiting these
Table 2. Treatment details and adverse events of SHARP eligible and non-eligible patients.
Variable All patients, N¼ 257 Eligible, N¼ 193 Non-eligible, N¼ 64 p valuea
Weeks of treatment, median (range) 13 (0–225) 13 (0–209) 9 (0–225) .052
Total tolerated daily dose, median (range) 400 (200–1400) 400 (200–1400) 400 (200–1000) .203
Treatment emergent adverse events
Any, all grades 203 (79) 150 (78) 53 (83) .082
Any, grade 3/4 140 (55) 104 (54) 36 (56) .742
Asthenia, all grades 76 (30) 56 (29) 20 (31) .734
Asthenia, grade 3/4 14 (5) 12 (6) 2 (3) .528
Dermatological, all grades 88 (34) 72 (37) 16 (25) .072
Dermatological, grade 3/4 29 (11) 24 (12) 5(8) .370
Gastrointestinal, all grades 94 (37) 69 (36) 25 (39) .634
Gastrointestinal, grade 3/4 32 (13) 27 (14) 5 (8) .274
Hematological, all grades 26 (10) 21 (11) 5 (8) .634
Hematological, grade 3/4 8 (3) 6 (3) 2 (3) 1.000
Hypertension, all grades 16 (6) 15 (8) 1 (2) .130
Hypertension, grade 3/4 5 (2) 5 (3) 0 (0) .336
Liver dysfunction, all grades 90 (35) 54 (28) 36 (56) <.001
Liver dysfunction, grade 3/4 72 (28) 44 (23) 28 (44) .001
Other, all grades 28 (11) 20 (10) 8 (13) .634
Other, grade 3/4 14 (5) 9 (5) 5 (8) .347
Treatment interruptions .998
None 172 (67) 129 (67) 43 (67)
1–2 interruptions 77 (30) 58 (30) 19 (30)
3 interruptions 8 (3) 6 (3) 2 (3)
Reason termination .030
Ongoing 6 (2) 6 (3) 0 (0)
Progression 127 (49) 104 (54) 23 (36)
Toxicity 34 (13) 25 (13) 9 (14)
Progression and adverse event 66 (26) 42 (22) 24 (38)
Other/unknown 24 (9) 16 (8) 5 (16)
Best radiological response (RECIST 1.1) .373
Complete response 0 (0) 0 (0) 0 (0)
Partial response 20 (8) 13 (7) 7 (11)
Stable disease 98 (38) 79 (41) 19 (30)
Progressive disease 106 (41) 77 (40) 29 (45)
Not evaluable 33 (13) 9 (9) 6 (19)
ap value applies to the ‘meeting’ versus ‘not meeting’ groups. p values <.05 are highlighted in bold.
RECIST: Response Evaluation Criteria in Solid Tumors; SHARP: Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol.
Table 3. Hazard ratios for overall survival in univariable and multivariable analysis.
Variable name, n (%)
Univariable analysis Multivariable analysis
HR 95% CI p valuea HR 95% CI p valuea
Not meeting SHARP inclusion criteria 1.81 1.35–2.44 <.001 1.78 1.32–2.41 <.001
Female sex 1.27 0.92–1.75 .152
Age >65 years 0.96 0.74–1.24 .729
HBV 1.02 0.71–1.47 .929
HCV 0.87 0.60–1.25 .437
Alcohol abuse 0.96 0.73–1.26 .747
Cirrhosis 1.11 0.81–1.53 .520
ECOG PS 2 (ref¼ ECOG 0-1) 1.57 1.01–2.44 .045 1.36 0.86–2.15 .191
BCLC stage C (ref: B) 1.23 0.91–1.65 .180
Number of nodes (ref ¼1 node) .087
2–3 nodes 0.86 0.60–1.24
>3 nodes/diffuse infiltrating 1.20 0.86–1.68
Tumor size >72mm 1.53 1.17–1.98 .002 1.27 0.95–1.70 .111
Macroscopic vascular invasion 1.44 1.11–1.88 .006 1.34 1.02–1.76 .036
Extrahepatic spread (ref¼ liver confined) 1.11 0.85–1.44 .456
AFP 400 1.76 1.35–2.30 <.001 1.60 1.22–2.11 .001
Received previous treatments 0.67 0.51–0.88 .004 0.84 0.61–1.15 .264
ap values <.05 are highlighted in bold.
AFP: a-fetoprotein; BCLC: Barcelona Clinic Liver Cancer classification; ECOG PS: Eastern Cooperative Oncology Group Performance status; HBV:
hepatitis virus B; HCV: hepatitis virus C; NAFLD/NASH: non-alcoholic fatty liver disease/non-alcoholic steatohepatitis; SHARP: Sorafenib
Hepatocellular Carcinoma Assessment Randomized Protocol.
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patients and carrying out such a trial [26]. Still, healthcare
authorities increasingly demand validation of (expensive)
drugs and both clinicians and patients are facing dilemmas
when considering treatment. The significant costs of sorafe-
nib therapy, which proved only to be cost-effective in
patients with compensated liver disease and when applying
proper dose adjustments, underlines the need of strict
patient selection [27,28]. Therefore, we conclude that cur-
rently there is insufficient evidence for sorafenib treatment
beyond the SHARP eligibility criteria, specifically in patients
with Child–Pugh B liver function, and that the registered
therapeutic indication and the BCLC staging system should
restrict treatment to Child–Pugh A patients. The limitations
of Child–Pugh A as a selection criterion and alternatives [i.e.,
Albumin-Bilirubin (ALBI) score] have been discussed previ-
ously [8,29]. Our findings support adherence to the current
guidelines with careful patient selection and dose-adjust-
ments according to the current evidence. This may reduce
non-beneficial exposure of patients to sorafenib toxicity and
the unnecessary healthcare costs.
Still, even in SHARP eligible patients further optimization
of sorafenib usage is possible, indicated by low response
rates, heterogeneity in survival outcomes and lack of a sig-
nificant improvement in patient-reported quality of life varia-
bles [2]. In the future, molecular biomarkers, i.e., tumor
profiling or biochemical serum markers, might aid in further
selecting the optimal candidates for sorafenib or future trials.
Our study has several limitations, including the retrospect-
ive design with its inherent drawbacks. Non-availability of
key parameters (i.e., Child–Pugh classification) led to exclu-
sion of some patients, as adherence to the SHARP eligibility
criteria could not be assessed. Furthermore, the retrospective
assessment of parameters that are subject to inter-observer
variability, such as ECOG PS or life expectancy, might have
caused inaccurate assessment. Strengths of our study include
the focus on unselected patients in the daily clinical practice
of two tertiary referral centers for HCC, covering roughly
30–40% of the Dutch HCC population. The construction of a
robust dataset was possible due to the standardized evalu-
ation of all patients in a multidisciplinary team meeting, pro-
spective monitoring of drug toxicity and standardized RECIST
1.1 response monitoring.
In conclusion, our results confirm that the trial outcomes
of sorafenib in advanced HCC are reproducible in daily clin-
ical practice, provided that the SHARP eligibility criteria are
respected. Based on our findings and the results of previous
studies, sorafenib usage should be restricted to Child–Pugh
A patients.
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